**Response to reviewers’ comments**

**Manuscript ID:** EJH-2020-0055

**Title:** Nonmyeloablative matched stem cell transplantation with optional reinforced stem cell infusion for hemoglobinopathies

Dear Editor,

We appreciate the editor and reviewers of “*European journal of Haematology*” for their effort and time in reviewing our manuscript. We have made some corrections and clarifications regarding the following points in the revised manuscript according to the reviewers’ comments. We are pleased that you are interested in our paper and hope that the revised manuscript will be suitable for publication in your journal. Again, we thank you for your constructive comments.

\*The numbers in the parentheses indicate the column in the marked-up version of the revised manuscript.

Sincerely,

Ki-Seong Eom, M.D., Ph. D.

Catholic Hematology Hospital, Seoul St. Mary’s Hospital, Leukemia Research Institute, College of Medicine, The Catholic University of Korea, 06591 Banpo-daero 222, Seocho-gu, Seoul, South Korea

dreom@catholic.ac.kr

Phone: +82-2-2258-6056, Fax: +82-2-780-1283

**Reviewer #1**

Q3. Gene therapy is another curative therapy for thalassemia and sickle disease. Therefore, the ‘only’ in sentence of ‘Allogeneic stem cell transplantation remains the only curative treatment option ~ hematologic disorders.’ (Page 3, Line 49) should be not correct.

A3. According to your comment, we have removed the ‘only’ in the corresponding sentence (Page 3; Line # 46).

Q4. Please, clarify whether the same donor or another donor was used in this study when patients received optional reinforced stem cell infusion.

A4. We described used the same donor when patients received optional reinforced stem cell infusion as follows: ‘they were administered reinforced infusion of SC from the same donors after total-nodal irradiation (TNI) at a single dose of 500 cGy.’ (Page 4; Line # 97).